Vanguard Group’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$2.5B Buy
14,392,082
+140,450
+1% +$25.6M 0.04% 429
2025
Q3
$2.72B Buy
14,251,632
+18,056
+0.1% +$3.2M 0.04% 407
2025
Q2
$2.56B Buy
14,233,576
+296,860
+2% +$51.6M 0.04% 404
2025
Q1
$2.36B Sell
13,936,716
-23,742
-0.2% -$3.9M 0.04% 407
2024
Q4
$2.11B Sell
13,960,458
-10,093
-0.1% -$1.57M 0.04% 445
2024
Q3
$2.17B Buy
13,970,551
+18,751
+0.1% +$2.8M 0.04% 434
2024
Q2
$1.91B Buy
13,951,800
+29,845
+0.2% +$4.09M 0.04% 448
2024
Q1
$1.85B Buy
13,921,955
+345,754
+3% +$44.9M 0.04% 468
2023
Q4
$1.87B Sell
13,576,201
-47,930
-0.4% -$6.3M 0.04% 445
2023
Q3
$1.66B Sell
13,624,131
-119,835
-0.9% -$16M 0.04% 443
2023
Q2
$1.93B Buy
13,743,966
+47,880
+0.3% +$6.6M 0.05% 416
2023
Q1
$1.94B Sell
13,696,086
-277,253
-2% -$39.7M 0.05% 405
2022
Q4
$2.19B Sell
13,973,339
-183,563
-1% -$26.4M 0.06% 362
2022
Q3
$1.74B Buy
14,156,902
+90,362
+0.6% +$11.9M 0.05% 395
2022
Q2
$1.87B Buy
14,066,540
+52,510
+0.4% +$7.16M 0.05% 385
2022
Q1
$1.92B Buy
14,014,030
+636,301
+5% +$88.7M 0.05% 431
2021
Q4
$2.31B Buy
13,377,729
+92,228
+0.7% +$14M 0.05% 390
2021
Q3
$1.93B Sell
13,285,501
-796,219
-6% -$117M 0.05% 431
2021
Q2
$1.86B Sell
14,081,720
-221,696
-2% -$29M 0.05% 448
2021
Q1
$1.84B Sell
14,303,416
-34,269
-0.2% -$4.22M 0.05% 415
2020
Q4
$1.71B Sell
14,337,685
-291,871
-2% -$35.6M 0.05% 410
2020
Q3
$1.67B Sell
14,629,556
-632,120
-4% -$74.7M 0.06% 364
2020
Q2
$1.74B Sell
15,261,676
-496,159
-3% -$52.6M 0.06% 333
2020
Q1
$1.27B Buy
15,757,835
+362,905
+2% +$37.6M 0.05% 369
2019
Q4
$1.64B Buy
15,394,930
+166,770
+1% +$17.4M 0.06% 384
2019
Q3
$1.63B Buy
15,228,160
+264,888
+2% +$27.2M 0.06% 357
2019
Q2
$1.52B Buy
14,963,272
+89,648
+0.6% +$8.61M 0.06% 369
2019
Q1
$1.34B Sell
14,873,624
-10,403
-0.1% -$901K 0.05% 406
2018
Q4
$1.24B Buy
14,884,027
+383,737
+3% +$36M 0.06% 379
2018
Q3
$1.56B Buy
14,500,290
+201,951
+1% +$22.1M 0.06% 356
2018
Q2
$1.57B Buy
14,298,339
+48,588
+0.3% +$5.06M 0.07% 336
2018
Q1
$1.43B Buy
14,249,751
+180,327
+1% +$18.5M 0.06% 367
2017
Q4
$1.39B Sell
14,069,424
-287,501
-2% -$27.3M 0.06% 378
2017
Q3
$1.34B Buy
14,356,925
+327,603
+2% +$34.8M 0.06% 358
2017
Q2
$1.56B Buy
14,029,322
+525,200
+4% +$55.5M 0.08% 287
2017
Q1
$1.33B Sell
13,504,122
-50,485
-0.4% -$4.81M 0.07% 326
2016
Q4
$1.25B Buy
13,554,607
+314,660
+2% +$27.1M 0.07% 323
2016
Q3
$1.12B Buy
13,239,947
+327,141
+3% +$27.5M 0.07% 344
2016
Q2
$1.05B Buy
12,912,806
+233,179
+2% +$17.8M 0.07% 338
2016
Q1
$906M Buy
12,679,627
+370,896
+3% +$24.9M 0.06% 382
2015
Q4
$876M Buy
12,308,731
+341,182
+3% +$22.9M 0.06% 366
2015
Q3
$736M Sell
11,967,549
-287,939
-2% -$20.1M 0.05% 414
2015
Q2
$889M Buy
12,255,488
+223,508
+2% +$16.5M 0.06% 367
2015
Q1
$925M Buy
12,031,980
+887,970
+8% +$63.6M 0.06% 353
2014
Q4
$747M Buy
11,144,010
+359,746
+3% +$22.7M 0.05% 403
2014
Q3
$654M Buy
10,784,264
+393,978
+4% +$24.3M 0.05% 421
2014
Q2
$610M Buy
10,390,286
+240,992
+2% +$14.1M 0.05% 440
2014
Q1
$588M Buy
10,149,294
+460,912
+5% +$24.7M 0.05% 428
2013
Q4
$519M Sell
9,688,382
-197,892
-2% -$11.7M 0.05% 458
2013
Q3
$611M Sell
9,886,274
-92,073
-0.9% -$5.51M 0.06% 367
2013
Q2
$605M Buy
+9,978,347
New +$594M 0.06% 342

Other funds holding DGX

Vanguard Group's DGX Position: Q4 2025 in Review

Vanguard Group increased its Quest Diagnostics (DGX) stake by 0.99% in Q4 2025, buying an estimated $25.6M and bringing the position to 14,392,082 shares worth $2.5B. The position accounts for 0.04% of the portfolio, ranked #429.

Vanguard Group first reported a position in DGX in Q2 2013 and has held it in 51 quarters since. The position peaked at $2.72B in Q3 2025. 1,048 funds tracked by Wall St. Rank hold DGX as of Q4 2025.

  • Vanguard Group held 14,392,082 shares of Quest Diagnostics worth $2.5B as of Q4 2025.
  • Vanguard Group bought 140,450 Quest Diagnostics shares in Q4 2025, an estimated $25.6M.
  • Quest Diagnostics made up 0.04% of Vanguard Group's portfolio in Q4 2025, its #429 holding.
  • Vanguard Group first reported a position in Quest Diagnostics in Q2 2013 and has held it in 51 quarters since.
  • Vanguard Group's Quest Diagnostics position peaked at $2.72B in Q3 2025.
  • 1,048 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.